Abstract
Dystonia is a hyperkinetic disabling movement disorder. In the dtsz hamster, a model of paroxysmal dystonia, pronounced antidystonic effects of the KV7.2-5 potassium channel opener retigabine and aggravation of dystonia by a selective KV7.2-5 blocker indicated a pathophysiological role of an abnormal expression of KV7 channels. We therefore investigated the expression of KV7 subunits in brains of dystonic hamsters. While KV7.2 and KV7.3 subunits were unaltered, lower KV7.5 mRNA levels became evident in motor areas and in limbic structures of dystonic hamsters. The KV7.2/3 subunit-preferring channel opener N-(6-chloropyridin-3-yl)-3,4- difluorobenzamide (ICA 27243; 10-30 mg/kg i.p.) failed to reduce the severity of dystonia in mutant hamsters, suggesting that the previously observed antidystonic action of retigabine is mediated by the activation of KV7.5 channels. The experiments indicate a functional relevance for KV7.5 channels in paroxysmal dystonia. We suggest that compounds highly selective for subtypes of KV7 channels, i.e. for KV7.5, may provide new therapeutic approaches.
Keywords: animal model, dyskinesia, dystonia, ICA 27243, KCNQ, voltage-gated potassium channels.
CNS & Neurological Disorders - Drug Targets
Title:Lower KV7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
Volume: 15 Issue: 1
Author(s): Svenja E. Sander, Mustansir Diwan, Roger Raymond, José N Nobrega and Angelika Richter
Affiliation:
Keywords: animal model, dyskinesia, dystonia, ICA 27243, KCNQ, voltage-gated potassium channels.
Abstract: Dystonia is a hyperkinetic disabling movement disorder. In the dtsz hamster, a model of paroxysmal dystonia, pronounced antidystonic effects of the KV7.2-5 potassium channel opener retigabine and aggravation of dystonia by a selective KV7.2-5 blocker indicated a pathophysiological role of an abnormal expression of KV7 channels. We therefore investigated the expression of KV7 subunits in brains of dystonic hamsters. While KV7.2 and KV7.3 subunits were unaltered, lower KV7.5 mRNA levels became evident in motor areas and in limbic structures of dystonic hamsters. The KV7.2/3 subunit-preferring channel opener N-(6-chloropyridin-3-yl)-3,4- difluorobenzamide (ICA 27243; 10-30 mg/kg i.p.) failed to reduce the severity of dystonia in mutant hamsters, suggesting that the previously observed antidystonic action of retigabine is mediated by the activation of KV7.5 channels. The experiments indicate a functional relevance for KV7.5 channels in paroxysmal dystonia. We suggest that compounds highly selective for subtypes of KV7 channels, i.e. for KV7.5, may provide new therapeutic approaches.
Export Options
About this article
Cite this article as:
Sander E. Svenja, Diwan Mustansir, Raymond Roger, Nobrega N José and Richter Angelika, Lower KV7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia, CNS & Neurological Disorders - Drug Targets 2016; 15 (1) . https://dx.doi.org/10.2174/1871527315666151110124136
DOI https://dx.doi.org/10.2174/1871527315666151110124136 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Molecular Linkages Between Diabetes and Alzheimer's Disease: Current Scenario and Future Prospects
CNS & Neurological Disorders - Drug Targets Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders – A Focus on the Modulation of Host Tissue Function
Mini-Reviews in Medicinal Chemistry Dysregulation of Glycogen Synthase Kinase-3 in Skeletal Muscle and the Etiology of Insulin Resistance and Type 2 Diabetes
Current Diabetes Reviews The Pathophysiology of Tics; An Evolving Story
Current Drug Therapy CXCL3 is a Potential Target for Breast Cancer Metastasis
Current Cancer Drug Targets The Toxicology of Chemokine Inhibition
Mini-Reviews in Medicinal Chemistry Formulation Approaches to Overcome Biopharmaceutical Limitations of Inhaled Peptides/Proteins
Current Pharmaceutical Design Is Technical-Grade Chlordane an Obesogen?
Current Medicinal Chemistry Identification of Novel NaV1.7 Antagonists Using High Throughput Screening Platforms
Combinatorial Chemistry & High Throughput Screening Brain Angiotensin II Involvement in Chronic Mental Disorders
Protein & Peptide Letters Voltammetric Sensing of Bilirubin Based on Nafion/Electrochemically Reduced Graphene Oxide Composite Modified Glassy Carbon Electrode
Current Analytical Chemistry Adult Stem Cells for Cartilage Tissue Engineering and Regeneration
Current Rheumatology Reviews Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews Commentary: Olfactory Dysfunction in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism The Role of Androgen Receptor Mutations in Prostate Cancer Progression
Current Genomics The Menstrual Cycle and Drug Metabolism
Current Drug Metabolism PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Psychiatric Disorders Associated with FXTAS
Current Psychiatry Reviews